NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Wednesday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 9.3 %

NASDAQ:NURO opened at $4.34 on Wednesday. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The stock has a 50-day simple moving average of $4.04 and a 200 day simple moving average of $3.84.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The firm had revenue of $0.59 million during the quarter. During the same period last year, the firm posted ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.